Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

UCB Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jean-Christophe Tellier

İcra Kurulu Başkanı

€6.7m

Toplam tazminat

CEO maaş yüzdesi	19.4%
CEO görev süresi	9.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.9yrs
Yönetim Kurulu ortalama görev süresi	10.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jean-Christophe Tellier'un ücretlendirmesi UCB'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€240m
Mar 31 2024	n/a	n/a	€292m
Dec 31 2023	€7m	€1m	€343m
Jun 30 2023	n/a	n/a	€332m
Mar 31 2023	n/a	n/a	€376m
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	€76k	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m

Tazminat ve Piyasa: Jean-Christophe 'ın toplam tazminatı ($USD 7.38M ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.83M ).

Tazminat ve Kazançlar: Jean-Christophe 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jean-Christophe Tellier (65 yo)

9.8yrs

Görev süresi

€6,662,655

Tazminat

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Christophe Tellier	CEO & Executive Director	9.8yrs	€6.66m	Veri yok
Sandrine Dufour	Executive VP	4.3yrs	Veri yok	Veri yok
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	5.1yrs	Veri yok	Veri yok
Denelle J. Johnson	Executive VP & General Counsel	1.5yrs	Veri yok	Veri yok
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	4.7yrs	Veri yok	Veri yok
Emmanuel Caeymaex	Executive VP & Chief Commercial Officer	9.7yrs	Veri yok	Veri yok
Fiona du Monceau	Executive Vice President of Patient Evidence	less than a year	€164.00k	Veri yok
Caroline Vancoillie	Chief Accounting Officer	11.6yrs	Veri yok	Veri yok
Alistair Henry	Executive VP & Chief Scientific Officer	less than a year	Veri yok	Veri yok
Antje Witte	Head of Investor Relations	14.8yrs	Veri yok	Veri yok
Gwendoline Ornigg	Head of Global Communication	no data	Veri yok	Veri yok
Veronique Toully	Head of Sustainability	no data	Veri yok	Veri yok

4.9yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: UCBB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Christophe Tellier	CEO & Executive Director	10.5yrs	€6.66m	Veri yok
Gerhard Mayr	Honorary Chairman	no data	€70.00k	Veri yok
Mark Eyskens	Honorary Chairman	19.8yrs	€15.50k	Veri yok
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	Veri yok
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	Veri yok
Diégo du de Bergendal	Honorary Chairman	3.5yrs	€87.50k	Veri yok
Karel Boone	Honorary Chairman	no data	€49.00k	Veri yok
Dame Davies	Independent Director	10.5yrs	€138.00k	Veri yok
Jonathan Peacock	Independent Chair of the Board	3.5yrs	€341.83k	Veri yok
Charles-Antoine Emmanuel Janssen	Director	12.5yrs	€108.50k	Veri yok
Jonkheer van Rijckevorsel	Director	10.5yrs	€86.00k	Veri yok
Rodolfo Savitzky	Independent Director	less than a year	Veri yok	Veri yok

10.5yrs

Ortalama Görev Süresi

73yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: UCBB 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.5 yıldır).

UCB Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Changes on Board of Directors

Recent updates

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

Dividend of €0.95 announced

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Revenue beats expectations

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €82.23

UCB Announces Changes on Board of Directors

New 90-day low: €84.30

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021

UCB SA (ENXTBR:UCB) completed the acquisition of Ra Pharmaceuticals, Inc. (NasdaqGM:RARX) from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi